Heartbeam, Inc. 8-K Filing
Ticker: BEATW · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1779372
| Field | Detail |
|---|---|
| Company | Heartbeam, Inc. (BEATW) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Heartbeam, Inc. (ticker: BEATW) to the SEC on Nov 21, 2025.
How long is this filing?
Heartbeam, Inc.'s 8-K filing is 1 pages with approximately 411 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2025-11-21 09:47:46
Filing Documents
- ea0266730-8k_heartbeam.htm (8-K) — 24KB
- 0001213900-25-113353.txt ( ) — 227KB
- beat-20251120.xsd (EX-101.SCH) — 3KB
- beat-20251120_def.xml (EX-101.DEF) — 26KB
- beat-20251120_lab.xml (EX-101.LAB) — 36KB
- beat-20251120_pre.xml (EX-101.PRE) — 25KB
- ea0266730-8k_heartbeam_htm.xml (XML) — 5KB
01
Item 8.01: Other Events On November 20, 2025, HeartBeam, Inc. (the "Company") received a Not Substantially Equivalent (NSE) letter from the U.S. Food and Drug Administration (FDA) related to the Company's 510(k) application for its 12-Lead Electrocardiogram (ECG) Synthesis Software. The Company stands behind its clinical data and will be working with the FDA to come to a resolution. In addition, the Company is evaluating launching its novel 3D ECG system, which received FDA 510(k) clearance in December 2024. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. HeartBeam, Inc. Date: November 21 , 2025 By: /s/ Timothy Cruickshank Name: Timothy Cruickshank Title: Chief Financial Officer 2